Ptc Therapeutics, Inc.

Bristol-Myers Squibb Compnay

Donald Thomas Corson

Young-Choon Moon

Soongyu Choi

Hongyan Qi

Liangxian Cao

William Jospeh Lennox

Nadarajan Tamilarasu

Seongwoo Hwang

Thomas W Davis

Neil Gregory Almstead

Jeffrey Allen Campbell

Jacques Banville

Michael A Walker

Marla L Weetall

Langdon Miller

Peter Seongwoo Hwang

Roger Remillard

Christopher Robert Trotta

Hatice Belgin Gulgeze

Zhengxian Gu

Harry H Miao

Tamil Arasu

Jason D Graci

William Joseph Lennox

Compounds, such as compounds of Formula (I), that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral replication or the production of viral RNA or DNA or viral protein and compositions comprising such Compounds are described. Also described are methods of reducing VEGF using such Compounds and methods for treating cancer and non-neoplastic conditions involving the administration of such Compounds. Further described are methods of inhibiting viral replication or the production of viral RNA or DNA or viral protein using such Compounds and methods for treating viral infections involving the administration of such Compounds. The Compounds may be administered as a single agent therapy or in combination with one or more additional therapies to a human in need of such treatments. 

Methods for treating cancer and non-neoplastic conditions

In accordance with the present invention, tetracyclic caboline derivatives that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, these compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

Tetra-cyclic carboline derivatives useful in the inhibition of angiogenesis

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

Carboline derivatives useful in the inhibition of angiogenesis

In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

Carboline derivatives useful in the treatment of cancer

The present invention relates a series of compounds of Formula Iwherein R, R, R, and B are as defined in the specification. The compounds are useful for the inhibition of HIV integrase and for the treatment of AIDS or ARC by administering compounds of the formula.

Acyl sulfonamides as inhibitors of HIV integrase

Growing community of inventors

Annandale, NJ, United States of America

Donald Thomas Corson